Hashiguchi, Masayuki



Faculty of Pharmacy, Department of Pharmacy 医薬品情報学講座 (Shiba-Kyoritsu)


Associate Professor


Books 【 Display / hide

  • スタンダード薬学シリーズⅡ6 医療薬学 Ⅴ. 薬物治療に役立つ情報

    HASHIGUCHI Masayuki, 2017.10

  • スタンダード薬学シリーズⅡ8 日本薬学会編 薬学研究

    HASHIGUCHI Masayuki, 2017.10

    Scope: 研究例19 データマイニング手法を用いた副作用シグナルの検出時期に関する検討

  • 医薬品情報学 第4版

    HASHIGUCHI Masayuki, 2016.03

    Scope: 6章医薬品情報の評価

  • 薬学テキストシリーズ 医薬品情報学―ワークブック

    HASHIGUCHI Masayuki, 2015.04

    Scope: 実践編 解説と演習 9薬剤疫学研究の評価

  • 高齢者ファーマナビゲーター COX-2阻害薬編(改訂版)

    HASHIGUCHI Masayuki, 2013.11

display all >>

Papers 【 Display / hide

  • Network Meta-Analysis Comparing Apixaban Versus Rivaroxaban in Morbidly Obese Patients With Atrial Fibrillation.

    Kido K, Shimizu M, Shiga T, Hashiguchi M.

    Am J Cardiol. 134   160 - 161 2020.09

    Research paper (scientific journal), Joint Work, Accepted

  • Early onset hydroxychloroquine retinopathy and a possible relationship with blood level: comment on the article Petri et al.

    Yokogawa N, Ohno-Tanaka A, Hashiguchi M, Shimizu M, Ozawa H, Ueno S, Shinoda K, Browning DJ.

    Arthritis Rheumatol.  2020.08

    Research paper (scientific journal), Joint Work, Accepted

  • Meta-Analysis Comparing Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Atrial Fibrillation

    Kido K., Shimizu M., Shiga T., Hashiguchi M.

    American Journal of Cardiology (American Journal of Cardiology)  126   23 - 28 2020.07

    ISSN  00029149

     View Summary

    © 2020 Elsevier Inc. The International Society of Thrombosis and Haemostasis recommends warfarin therapy over direct oral anticoagulants (DOACs) in patients with a body mass index >40 kg/m2 or weight > 120 kg due to limited clinical data in morbidly obese patients. The aim of the meta-analysis was to compare DOACs with warfarin in morbidly obese patients with atrial fibrillation (AF) and to optimize an anticoagulation therapy in the population. MEDLINE, Embase, Google Scholar, Web of Science, and Cochrane Library database searches for relevant articles through December 23, 2019 were performed. Total 5 studies for the event rate of stroke or systemic embolism (SE) and 4 studies for major bleeding were included in the meta-analysis. It showed that there was no statistically significant difference in stroke or SE event rate between the DOAC and warfarin groups (odds ratio: 0.85; 95% confidence interval: 0.60, 1.19; p = 0.35; I2 = 0 %). The DOAC use was significantly associated with a lower major bleeding event rate compared the warfarin group (odds ratio: 0.63; 95% confidence interval: 0.43, 0.94; p = 0.02; I2 = 30%). In conclusion, DOACs should be considered as an oral anticoagulant for preventing stroke or SE in morbidly obese patients with AF. A randomized controlled trial comparing a DOAC with warfarin is needed to confirm our meta-analysis results in morbidly obese patients with AF.

  • Factors Contributing to the Systemic Clearance of Infliximab with Long-Term Administration in Japanese Patients with Crohn’s Disease: Analysis Using Population Pharmacokinetics.

    Matsuoka K, Hamada S, Shimizu M, Nanki K, Mizuno S, Kiyohara H, Arai M, Sugimoto S, Iwao Y, Ogata H, Hisamatsu T, Naganuma M, Kanai T, Mochizuki M, Hashiguchi M.

    Int J Clin Pharmacol Ther.  2019.10

    Research paper (scientific journal), Joint Work, Accepted

  • Long-term effect of NUDT15 R139C on hematologic indices in inflammatory bowel disease patients treated with thiopurine

    Akiyama S., Matsuoka K., Fukuda K., Hamada S., Shimizu M., Nanki K., Mizuno S., Kiyohara H., Arai M., Sugimoto S., Iwao Y., Ogata H., Hisamatsu T., Naganuma M., Motobayashi M., Suzuki K., Takenaka K., Fujii T., Saito E., Nagahori M., Ohtsuka K., Mochizuki M., Watanabe M., Hashiguchi M., Kanai T.

    Journal of Gastroenterology and Hepatology (Australia) (Journal of Gastroenterology and Hepatology (Australia))  34 ( 10 ) 1751 - 1757 2019.10

    ISSN  08159319

     View Summary

    © 2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd Background and Aim: A missense variant of the nucleoside diphosphate-linked moiety X-type motif 15 (NUDT15) gene (R139C) predisposes Asian patients with inflammatory bowel disease (IBD) to thiopurine-induced leukopenia. This study evaluates the long-term effect of NUDT15 R139C heterozygosity on hematological parameters during thiopurine administration. Methods: We enrolled 83 Japanese IBD patients who were on anti-tumor necrosis factor-α agents and had used thiopurine. NUDT15 R139C was genotyped by polymerase chain reaction. We retrospectively reviewed patient clinical charts to collect data on white blood cell (WBC) count, mean corpuscular volume (MCV), hemoglobin, and platelet count during the 24 months following thiopurine initiation. Results: The included patients had either Crohn's disease (54; 65.1%) or ulcerative colitis (29; 34.9%). Genotyping of NUDT15 R139C identified 62 patients (74.7%) of genotype C/C and 21 (25.3%) of genotype C/T. The median dose of thiopurine was lower in the C/T group than in the C/C group after starting thiopurine. At 6 months, the mean WBC count of the C/T group became significantly lower than that of the C/C group (P = 0.008) and remained lower through the 24 months. The C/T group developed grade 2–4 leukopenia by 6 months, which persisted through 12–24 months. The mean MCV in the C/T group became higher than that of the C/C group after 3 months. Conclusions: NUDT15 R139C heterozygosity affected the WBC count and MCV for 24 months after thiopurine administration. Our results indicate that careful monitoring of leukopenia and dose adjustment are necessary throughout treatment in IBD patients heterozygous for the NUDT15 R139C.

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

Reviews, Commentaries, etc. 【 Display / hide

  • 【医薬品副作用学(第3版)上-薬剤の安全使用アップデート-】副作用総論 副作用重篤度分類基準

    橋口正行, 望月眞弓

    日本臨床 77 ( 増刊3 ) 38 - 48 2019.06

    Introduction and explanation (commerce magazine), Joint Work

  • 【医薬品副作用学(第3版)上-薬剤の安全使用アップデート-】副作用総論 副作用・感染症報告制度

    橋口正行, 望月眞弓

    日本臨床 77 ( 増刊3 ) 25 - 37 2019.06

    Introduction and explanation (commerce magazine), Joint Work

  • Guidelines for Therapeutic Drug Monitoring of Cardiovascular Drugs Clinical Use of Blood Drug Concentration Monitoring (JCS 2015)- Digest Version

    Aonuma K, Shiga T, Atarashi H, Doki K, Echizen H, Hagiwara N, Hasegawa J, Hayashi H, Hirao K, Ichida F, Ikeda T, Maeda Y, Matsumoto N, Sakaeda T, Shimizu W, Sugawara M, Totsuka K, Tsuchishita Y, Ueno K, Watanabe E, Hashiguchi M, Hirata S, Kasai H, Matsumoto Y, Nogami A, Sekiguchi Y, Shinohara T, Sugiyama A, Sumitomo N, Suzuki A, Takahashi N, Yukawa E, Homma M, Horie M, Inoue H, Ito H, Miura T, Ohe T, Shinozaki K, Tanaka K.

    Circ J. 81 ( 4 ) 581 - 612 2017.03

    Introduction and explanation (scientific journal), Joint Work

  • 循環器薬の薬物血中濃度モニタリングに関するガイドライン

    HASHIGUCHI Masayuki

    TDM研究 33 ( 3 ) 123 - 157 2016

    Introduction and explanation (scientific journal), Joint Work

  • 患者副作用情報報告の意義、報告システムの構築と試行.


    都薬雑誌 (東京都薬剤師会)  34(9)   13-17 2012.09

    Introduction and explanation (scientific journal), Joint Work

display all >>

Presentations 【 Display / hide

  • ヒト滑膜細胞を用いた Methotrexate-polyglutamates 体の抗リウマチ効果およびその制御機構の解明

    HASHIGUCHI Masayuki

    第37回日本臨床薬理学会学術総会, 2016.12, Oral Presentation(general)

  • 薬局におけるセルフチェックを支援する体制の構築に関する研究

    HASHIGUCHI Masayuki

    第38回日本臨床栄養学会総会/第37回日本臨床栄養協会総会 第14回大連合大会, 2016.10, Oral Presentation(general)

  • 日本における一般用医薬品の添付文書理解度調査の実施可能性に関する研究

    HASHIGUCHI Masayuki

    第26回日本医療薬学会年会, 2016.09, Oral Presentation(general)

  • 使用成績調査データベースを用いたHMG-CoA還元酵素阻害薬による糖尿病・高血糖発症リスク因子の検討

    HASHIGUCHI Masayuki

    医療薬学フォーラム2016/第24回クリニカルファーマシーシンポジウム, 2016.06, Poster (general)

  • 一般用医薬品添付文書の理解度を改善するための形式に関する研究

    HASHIGUCHI Masayuki

    第18回日本医薬品情報学会総会・学術大会, 2016.06, Poster (general)

display all >>

Awards 【 Display / hide

  • 第30回(2019年度)臨床薬理研究振興財団賞 学術論文賞

    2019.12, 一般社団法人 日本臨床薬理学会, Risk Factors for Hyperuricemia with HMG-CoA Reductase Inhibitors Using a Postmarketing Surveillance Database in Japan.

    Type of Award: Celebration by Official journal of a scientific society or Academic Journal

  • 第五回藤田賞ー薬剤疫学分野ー


     View Description


  • 第25回(2014年度)臨床薬理研究振興財団賞学術論文賞

    2014.12, Relationship between Genetic Polymorphisms and mRNA Expression of Dihydrofolate Reductase Enzyme in a Healthy Japanese Population

    Type of Award: Awards of National Conference, Council and Symposium

     View Description

    Relationship between Genetic Polymorphisms and mRNA Expression of Dihydrofolate Reductase Enzyme in a Healthy Japanese Population

  • 日本医薬品情報学会論文賞

    橋口正行、金子梨沙、保坂藍、植田恵子、小寺典子、中村眞弓、榊原幹夫、黒川達夫、望月眞弓., 2013.08, 日本医薬品情報学会, 一般用医薬品の添付文書理解度調査法の開発、ー理解度への影響因子の検討ー.

  • 第 1 回 臨床薬理研究振興財団 研究大賞

    Hashiguchi M., 2008.11, 日本臨床薬理研究振興財団, メトトレキサートによる関節リウマチ個別化療法の確立のための臨床薬理学的研究.


Courses Taught 【 Display / hide











display all >>